Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Oncologist or gynecologist.
Responsible for treating ≥4-10 (depending on country) ABC/MBC patients who meet the eligibility criteria.
Agrees to participate in the study and complete the case report forms (CRFs) within the data collection period.
HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease.
Received palbociclib as a first line therapy.
No prior or current enrolment in an interventional clinical trial for ABC/MBC.
Minimum of six months of follow up data since palbociclib initiation.
You may not be if
Qualified less than 2 years ago or more than 35 years ago.
Participated in observational research for ABC/MBC in the last 3 months.
Have not prescribed either palbociclib plus fulvestrant or palbociclib plus aromatase inhibitor as first line therapy.
Clareo Health | Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.
